We Help Companies Find New Sales Opportunities
Avecia is to sell Avecia Inkjet, the Manchester-based supplier of ink dyes with 340 staff, to Fuji Photo of Japan for £150m.
Avecia is to sell its pharmaceutical synthesis business to Nicholas Piramal India for £9.5m, involving the transfer of 350 staff at sites in Huddersfield, Grangemouth, Billingham and the US.
Avecia is to sell its NeoResins coatings and inks business, which has 635 staff at five sites worldwide, to DSM of the Netherlands for £355m.
Avecia is to sell its biocides business, which has 290 staff at sites in Huddersfield, Grangemouth, Manchester and the US, to Arch Chemicals of the US for £118m.
Avecia has agreed to sell its Metal Extraction Products and Intermediates & Stabilizers operations in the US to Cytec for about £60m, which will involve the transfer of 200 staff.
Avecia is seeking planning permission for the £1.9m extension of its pharmaceutical laboratory facilities in Billingham.
Avecia has confirmed plans to build a £70m biological medicines plant in Billingham by 2005, creating 300 jobs at what will be the world's largest pharmaceutical microbial fermentation facility.
Avecia is seeking permission to build a new bio-pharmaceutical manufacturing facility at its site in Billingham, with the creation of about 300 jobs.
Avecia is planning to sell Stahl, the Dutch supplier of leather finishing chemicals with 1,500 staff in 28 countries, to a management buy-out for £232m.